Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180318 | 0.98 | PRKCA (0.49) | PRKCANAAADGKA | |
| SCHEMBL3628006 | 0.98 | PRKCA (0.49) | PRKCANAAADGKA | |
| SCHEMBL1517935 | 0.92 | PRKCA (0.41) | PRKCANAAADGKANPC1CYP19A1 | |
| SCHEMBL20589363 | 0.91 | PRKCA (0.38) | PRKCANAAACYP19A1 | |
| SCHEMBL6551912 | 0.89 | HSD17B10 (0.39) | PRKCANPC1CYP19A1 | |
| SCHEMBL371437 | 0.86 | CNR2 (0.41) | PRKCANAAADGKA | |
| SCHEMBL977159 | 0.85 | MAP3K14 (0.38) | NPC1CYP19A1 | |
| SCHEMBL9682839 | 0.85 | PRKCA (0.33) | PRKCANAAANPC1 | |
| SCHEMBL10480498 | 0.82 | PRKCA (0.32) | PRKCA | |
| SCHEMBL11095324 | 0.82 | NPC1 (0.36) | PRKCANPC1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180432-A1 | LIBRARY GENERATION FOR NEXT-GENERATION SEQUENCING | Abbott Molecular Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016025872-A1 | LIBRARY GENERATION FOR NEXT-GENERATION SEQUENCING | ABBOTT MOLECULAR INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160046987-A1 | LIBRARY GENERATION FOR NEXT-GENERATION SEQUENCING | ABBOTT MOLECULAR INC. | 2016-02-18 | — | — | US | disclosed |
| EP-2106812-B1 | Methods of Making and Using Surfactant Polymers | NANOMIMETICS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9125969-B2 | Methods of making and using surfactant polymers | NANOMIMETICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120245288-A1 | METHODS OF MAKING AND USING SURFACTANT POLYMERS | NANOMIMETICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2006132446-A9 | METHOD OF MANUFACTURING PROBE-IMMOBILIZED CARRIER | CANON KABUSHIKI KAISHA (JP) | 2012-09-13 | — | — | WO | disclosed |
| US-8163302-B2 | Methods of making and using surfactant polymers | NANOMIMETICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2106812-A2 | Methods of Making and Using Surfactant Polymers | NanoMimetics, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090191566-A1 | Kits for Isolating Nucleic Acids Using Multifunctional Group-Coated Solid Phase Carriers | AGENCOURT BIOSCIENCE CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
| US-7276474-B2 | Methods of making and using surfactant polymers | NANOMIMETICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1776458-A2 | METHODS OF ISOLATING NUCLEIC ACIDS USING MULTIFUNCTIONAL GROUP-COATED SOLID PHASE CARRIERS | Agencourt Bioscience Corporation (US) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006132446-A1 | METHOD OF MANUFACTURING PROBE-IMMOBILIZED CARRIER | CANON KABUSHIKI KAISHA (JP) | 2006-12-14 | — | — | WO | disclosed |
| US-20060177836-A1 | Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers | AGENCOURT BIOSCIENCE CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2006015326-A2 | METHODS OF ISOLATING NUCLEIC ACIDS USING MULTIFUNCTIONAL GROUP-COATED SOLID PHASE CARRIERS | AGENCOURT BIOSCIENCE CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050008603-A1 | Methods of making and using surfactant polymers | NANOMIMETICS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-6759388-B1 | COMBLIKE POLYMERS; INCREASING BLOOD BIOCOMPATIBILITY OF IMPLANTS; SUCH AS OLIGOSACCHARIDE OR OLIGOPEPTIDE SIDE CHAIN DERIVATIZED POLYVINYL AMIDE, POLYVINYL ALCOHOL OR POLYLYSINE | NANOMIMETICS, INC. | 2004-07-06 | — | — | US | disclosed |
| EP-1086149-A4 | SURFACTANTS THAT MIMIC THE GLYCOCALYX | MARCHANT ROGER E (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1086149-A1 | SURFACTANTS THAT MIMIC THE GLYCOCALYX | Marchant, Roger E. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999055742-A1 | SURFACTANTS THAT MIMIC THE GLYCOCALYX | MARCHANT ROGER E (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008603-A1 | Methods of making and using surfactant polymers | MSR1, CD14, PLOD3 | PRKCA 2602/4885NAAA 1899/4885DGKA 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.